Key Performance
More- Earnings Score: 18
- Momentum Score: 18
- True Yield: N/A
- Financial Health Score: 54
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
The Rosen Law Firm reminds investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) of the May 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false statements regarding inconsistent clinical trial results for reproxalap and failed to disclose material information about the company's business and operations, resulting in investor losses.
05/28/2026, 9:55 PM • GlobeNewswire
Rosen Law Firm is notifying investors in Babcock & Wilcox Enterprises, Aldeyra Therapeutics, and ChampionX Corporation of ongoing securities class action lawsuits. The B&W lawsuit alleges the company made false statements regarding a Power Generation contract with Applied Digital, with its largest shareholder BRC standing on both sides of the deal. Investors with losses exceeding $100K are encouraged to secure counsel before upcoming deadlines.
05/28/2026, 3:36 PM • GlobeNewswire
A class action lawsuit has been filed against Aldeyra Therapeutics (ALDX) for allegedly issuing false and misleading statements regarding reproxalap clinical trial results. The lawsuit claims the trial results were inconsistent and unreliable. Investors who purchased shares between November 3, 2023 and March 16, 2026 have until May 29, 2026 to apply as lead plaintiff.
05/26/2026, 5:45 PM • GlobeNewswire
Rosen Law Firm reminds investors in Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) who purchased securities between November 3, 2023 and March 16, 2026 of the May 29, 2026 deadline to join a securities class action lawsuit. The lawsuit alleges that defendants made false statements regarding reproxalap clinical trial results and failed to disclose inconsistencies that rendered positive findings unreliable, causing investor losses.
05/24/2026, 8:34 PM • GlobeNewswire
Rosen Law Firm reminds investors of Aldeyra Therapeutics who purchased securities between November 3, 2023 and March 16, 2026 of the May 29, 2026 lead plaintiff deadline in a securities class action lawsuit. The lawsuit alleges that defendants made false and misleading statements regarding reproxalap clinical trial results, claiming the results were inconsistent and unreliable, causing investor damages.
05/24/2026, 8:34 PM • GlobeNewswire
A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. alleging that the company made false and misleading statements regarding reproxalap clinical trial results. The complaint claims trial results were inconsistent and unreliable, rendering defendants' statements about the company's business and prospects materially false. Investors who purchased Aldeyra securities between November 3, 2023 and March 16, 2026 may be eligible to join the case.
05/20/2026, 12:00 PM • GlobeNewswire
Holzer & Holzer, LLC announced lead plaintiff deadlines for shareholder class action lawsuits against three companies: Vital Farms (VITL) for alleged false statements regarding enterprise resource planning system implementation, Super Micro Computer (SMCI) for alleged non-disclosure of export control compliance issues, and Aldeyra Therapeutics (ALDX) for alleged misstatements regarding reproxalap clinical trials. All deadlines are set for late May 2026.
05/20/2026, 8:00 AM • GlobeNewswire
Rosen Law Firm is soliciting investors who purchased securities in Aldeyra Therapeutics, Babcock & Wilcox Enterprises, and Upstart Holdings during specified periods to join securities class action lawsuits. The firm alleges that defendants made false or misleading statements regarding clinical trial results, business operations, and financial prospects. Investors have until May 29, 2026 to serve as lead plaintiffs.
05/18/2026, 6:45 PM • GlobeNewswire
Rosen Law Firm is soliciting investors who purchased securities of Babcock & Wilcox Enterprises, Aldeyra Therapeutics, and Upstart Holdings during specified periods to join class action lawsuits. The B&W lawsuit alleges the company made false statements regarding a Power Generation contract with Applied Digital, with undisclosed conflicts of interest involving its largest shareholder BRC Group Holdings. The firm emphasizes its track record in securities litigation and encourages investors to act before the June 15, 2026 lead plaintiff deadline.
05/18/2026, 6:24 PM • GlobeNewswire
Aldeyra Therapeutics faces a securities class action lawsuit after an FDA Complete Response Letter exposed alleged failures in clinical trial evidence for its lead dry eye disease drug reproxalap. ALDX shares collapsed 70.7% on March 17, 2026, closing at $1.24. Investors who purchased securities between November 3, 2023 and March 16, 2026 can apply to be lead plaintiff by May 29, 2026.
05/18/2026, 1:00 PM • GlobeNewswire
A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. alleging that the company made false and misleading statements regarding reproxalap clinical trial results. The complaint claims trial results were inconsistent and unreliable, rendering statements about the company's business and prospects materially false. Investors who purchased Aldeyra securities between November 3, 2023 and March 16, 2026 may be eligible to join the lawsuit.
05/13/2026, 1:00 PM • GlobeNewswire
A class action lawsuit has been filed against Aldeyra Therapeutics, Inc. for allegedly issuing false and misleading statements regarding reproxalap clinical trial results. The lawsuit covers investors who purchased securities between November 3, 2023 and March 16, 2026. Investors have until May 29, 2026 to apply as lead plaintiff.
05/11/2026, 8:47 PM • GlobeNewswire
Aldeyra Therapeutics faces a securities class action lawsuit after the FDA rejected its lead drug candidate reproxalap, citing inconsistent and unreliable clinical trial data. ALDX stock plummeted 70.7% ($2.99 per share) on March 17, 2026. Investors who purchased shares between November 3, 2023 and March 16, 2026 may be eligible to participate in the class action, with the lead plaintiff application deadline set for May 29, 2026.
05/11/2026, 4:00 PM • GlobeNewswire
Rosen Law Firm is reminding investors who purchased Aldeyra Therapeutics securities between November 3, 2023 and March 16, 2026 of the May 29, 2026 lead plaintiff deadline in a securities class action. The lawsuit alleges that defendants made false and misleading statements about reproxalap clinical trial results, claiming the results were inconsistent and unreliable, thereby misrepresenting the company's business and prospects.
05/09/2026, 7:47 PM • GlobeNewswire
Rosen Law Firm is pursuing a securities class action lawsuit against Aldeyra Therapeutics for allegedly making false and misleading statements about reproxalap clinical trial results. The lawsuit claims defendants failed to disclose that trial results were inconsistent and unreliable. Investors who purchased ALDX securities between November 3, 2023 and March 16, 2026 may be eligible for compensation, with a lead plaintiff deadline of May 29, 2026.
05/03/2026, 8:19 AM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/02/2026
Company Profile
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, which is in Phase III clinical trial for the treatment of dry eye disease and allergic conjunctivitis; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment of primary vitreoretinal lymphoma and retinitis pigmentosa. The company also develops ADX-629, an orally administered RASP modulator that is in Phase 2 clinical trials for the treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication. In addition, it develops preclinical RASP platforms, including ADX 248, ADX 246, and other novel RASP modulators for the treatment of various diseases associated with RASP. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.